TARS - Company ID 0001819790
The table below shows Tarsus Pharmaceuticals, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$24.65M | -$20.65M | -$37.79M | -$21.97M | -$15.29M | -$11.79M |
| Capital expenditure | $5.82M | $590.00K | $174.00K | $340.00K | $161.00K | $175.00K |
| Investing cash flow | -$58.56M | -$34.94M | -$102.22M | $11.29M | -$161.00K | -$175.00K |
| Dividends paid | - | - | - |
Tarsus Pharmaceuticals, Inc. reported operating cash flow of -$12.45M for fiscal year 2025. That is up 85.0% from -$83.03M in fiscal 2024. Over the 7 fiscal years shown, operating cash flow declined from -$3.67M (FY 2019) to -$12.45M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $1.20M | $136.56M | $108.77M | $5.01M | $19.13M | $19.00K |